![]() |
|
![]() |
| Home | About and More Information | Transporter Data Index |
Synonyms: Oatp1, OATP-1, Slc21a1, Slc21a3
Entrez Gene Link
No expression data.
| Substrate | Km (μM) | Cell System | Reference |
|---|---|---|---|
| Ammonium perfluorooctanoate | 162.2 | CHO cells | Yang, 2009 |
| Estrone sulfate | 22.9 | CHO cells | Yang, 2009 |
ND = not determined
1 denotes drugs that can potentially be used as in vitro substrates for studies of the transporter as defined by the FDA as of March 2022
2 denotes drugs that can potentially be used as in vitro inhibitors for studies of the transporter as defined by the FDA as of March 2022
3 denotes drugs that can potentially be used as clinical substrates for studies of the transporter as defined by the FDA as of March 2022
4 denotes drugs that can potentially be used as clinical inhibitors for studies of the transporter as defined by the FDA as of March 2022
| Inhibitor | IC50 (μM) | Ki (μM) | Substrate used | Cell System | Reference |
|---|---|---|---|---|---|
| Perfluorodecanoic acid | - | 26.8 | Estrone sulfate | CHO cells | Yang, 2009 |
| Perfluoroheptanoic acid | - | 398.9 | Estrone sulfate | CHO cells | Yang, 2009 |
| Perfluorohexanoic acid | - | 1857.8 | Estrone sulfate | CHO cells | Yang, 2009 |
| Perfluorononanoic acid | - | 44.6 | Estrone sulfate | CHO cells | Yang, 2009 |
| Perfluorooctanoic acid | - | 83.8 | Estrone sulfate | CHO cells | Yang, 2009 |
ND = not determined
1 denotes drugs that can potentially be used as in vitro substrates for studies of the transporter as defined by the FDA as of March 2022
2 denotes drugs that can potentially be used as in vitro inhibitors for studies of the transporter as defined by the FDA as of March 2022
3 denotes drugs that can potentially be used as clinical substrates for studies of the transporter as defined by the FDA as of March 2022
4 denotes drugs that can potentially be used as clinical inhibitors for studies of the transporter as defined by the FDA as of March 2022
No drug-drug interaction information.